DBVDBV TechnologiesDBV info
$0.64info-1.28%24h
Global rank22214
Market cap$61.86M
Change 7d3.17%
YTD Performance-67.35%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    DBV Technologies (DBV) Stock Overview

    DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and eosinophilic esophagitis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

    DBV Stock Information

    Symbol
    DBV
    Address
    177-181 Avenue Pierre BrossoletteMontrouge, 92120France
    Founded
    -
    Trading hours
    -
    Website
    https://www.dbv-technologies.com
    Country
    🇫🇷 France
    Phone Number
    33 1 55 42 78 78

    DBV Technologies (DBV) Price Chart

    -
    Value:-

    DBV Technologies Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $0.6431603314181183
    N/A
    Market Cap
    $61.86M
    N/A
    Shares Outstanding
    96.19M
    N/A
    Employees
    97.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org